The Legal Risks of Platform-Based Medical Services

A German legal expert has warned that online platforms offering cannabis treatment consultations—even without direct prescription services—remain in a legally precarious position under current healthcare and advertising laws, according to a June 2026 analysis by Anwalt.de. The risk arises when websites go beyond neutral information and begin facilitating patient requests for treatment, potentially violating strict regulations on telemedicine and drug promotion.

German law distinguishes sharply between informational platforms and those that actively mediate medical services. While websites providing general education on cannabis-based therapies may operate within legal gray areas, any platform that connects patients with doctors or encourages treatment-seeking behavior crosses into regulated territory, said Dr. Markus Weber, a healthcare law specialist at the University of Heidelberg. “The moment a site transitions from education to facilitation, it becomes a telemedicine provider—and that triggers compliance obligations under the Heilmittelwerbegesetz (HMWG) and Telemedizinverordnung,” Weber told Anwalt.de.

This legal ambiguity has grown as demand for remote cannabis consultations surges, particularly in regions where in-person access is limited. A 2025 study by the Bundesärztekammer (German Medical Association) found that 42% of surveyed patients with chronic pain had sought online advice for cannabis therapies, up from 18% in 2023. Yet only 12% of these platforms explicitly disclaim medical advice, leaving them exposed to enforcement actions.

Why the legal risk persists

Three key factors keep the issue contentious:

• Cross-border complications: Platforms operating from EU jurisdictions with looser cannabis regulations (e.g., Malta or the Netherlands) can target German users without local oversight. The Bundesverband Deutscher Apothekerverbände (ABDA) has flagged at least seven such sites currently advertising to German patients.
• Enforcement gaps: While German authorities have shut down several unlicensed telemedicine platforms since 2024, cannabis-specific cases remain rare. The Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) confirmed to Anwalt.de that no cannabis-focused platforms have faced penalties under the HMWG to date.
• Patient demand vs. liability: A 2026 survey by YouGov revealed that 58% of German adults with qualifying conditions would use an online cannabis consultation service if legally available—yet only 3% trust platforms to remain purely informational.

What happens next for platforms and patients?

Legal experts predict two likely outcomes. First, platforms may adopt stricter disclaimers and third-party verification systems to distance themselves from treatment facilitation. The Deutsche Apotheker Zeitung reported that at least three German pharmacy chains are testing partnerships with “educational-only” cannabis sites to mitigate liability.

Second, regulatory clarity could emerge as early as 2027, when Germany’s Bundesgesundheitsministerium (BMG) is expected to finalize guidelines on digital cannabis advice. A draft leaked to Handelsblatt suggests platforms may be allowed to offer “pre-screening” tools—provided they direct users to licensed providers without endorsing specific treatments.

For patients, the immediate advice from Weber is cautious: “If you’re considering cannabis therapy, use platforms that explicitly state they do not provide medical advice. Otherwise, you risk both legal exposure for the site and unreliable treatment pathways.” The Bundesärztekammer echoes this, warning that unregulated consultations could lead to improper dosing or interactions with other medications.

How this compares to other EU markets

Germany’s approach contrasts with neighboring countries where cannabis telemedicine is more explicitly regulated. In the Netherlands, for example, the Kolenbrander Group operates a licensed online platform for medical cannabis referrals, while Italy’s Ministero della Salute issued clear guidelines in 2025 allowing teleconsultations for cannabis-based therapies—provided doctors are registered with the national health system.

By comparison, Germany’s patchwork of state-level cannabis laws and federal telemedicine restrictions creates a “legal vacuum” for online providers, according to Weber. “Other EU states have treated this as a healthcare service from day one. Germany is still treating it as an advertising problem,” he said.

For now, platforms navigating this space must balance commercial opportunity with the risk of enforcement. The Bundesverband Digitale Wirtschaft (BVDW) estimates that up to €50 million in investment has flowed into German cannabis-edtech startups since 2024—yet none have secured definitive legal clearance to operate at scale.